

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

14  
REC'D 09 OCT 2001

WIFO

Applicant's or agent's file reference <b>310307.90134</b>	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. <b>PCT/US00/13960</b>	International filing date (day/month/year) <b>19 May 2000 (19.05.2000)</b>	Priority date (day/month/year) <b>22 May 1999 (23.05.1999)</b>
International Patent Classification (IPC) or national classification and IPC <b>IPC(7): C12P 19/34 and US Cl.: 435/91.2</b>		
Applicant <b>EPICENTRE TECHNOLOGIES CORPORATION</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 3 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand <b>30 November 2000 (30.11.2000)</b>	Date of completion of this report <b>05 September 2001 (05.09.2001)</b>
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer <b>Gary Jones</b>  Telephone No. 703-308-0196

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/13960

## I. Basis of the report

1. With regard to the elements of the international application:\*

☒ the international application as originally filed.

☒ the description:

pages 1-24 as originally filed

pages NONE, filed with the demand

pages NONE, filed with the letter of \_\_\_\_\_.

☒ the claims:

pages 25-30 as originally filed

pages NONE, as amended (together with any statement) under Article 19

pages NONE, filed with the demand

pages NONE, filed with the letter of \_\_\_\_\_.

☒ the drawings:

pages 1-2 as originally filed

pages NONE, filed with the demand

pages NONE, filed with the letter of \_\_\_\_\_.

☐ the sequence listing part of the description:

pages NONE as originally filed

pages NONE, filed with the demand

pages NONE, filed with the letter of \_\_\_\_\_.

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  
These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in printed form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

☒ the description, pages NONE

☒ the claims, Nos. NONE

☒ the drawings, sheets/fig NONE

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/13960

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. STATEMENT

Novelty (N)

Claims 1-38

YES

Claims NONE

NO

Inventive Step (IS)

Claims NONE

YES

Claims 1-38

NO

Industrial Applicability (IA)

Claims 1-38

YES

Claims NONE

NO

### 2. CITATIONS AND EXPLANATIONS (Rule 70.7)

Claims 1-38 lack an inventive step under PCT Article 33(3) as being obvious over Riggs et al in view of Swaminathan et al. The claims are drawn to a purified thermostable template-dependent DNA polymerase from the species *B. stearothermophilus* comprising reverse transcriptase activity in the presence of magnesium ions at a concentration of at least one mM and in the substantial absence of manganese ions.

Riggs et al teach "a purified thermostable DNA polymerase enzyme produced by expression of a gene encoding a DNA polymerase derived from *B. stearothermophilus*..." Riggs does not teach that the enzyme has reverse transcriptase activity, or levels of magnesium and manganese ions.

Swaminathan et al. teach reverse transcriptase products from *B. stearothermophilus* at different concentrations of MnCl and in the presence of magnesium.

It would have been obvious to one of ordinary skill in the art to combine these references because it would have been obvious to vary the levels of Mn and Mg in order to optimize the reaction.

NEW CITATIONS